Braidwell LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Braidwell LP reported 51 stock positions worth $1.8 billion. Its top holding was Apogee Therapeutics (APGE) at 6.9% of the portfolio, followed by Neurocrine Biosciences (NBIX, 5.7%) and Argenx SE - ADR (ARGX, 4.9%). Compared with Q4 2023, it opened 16 new positions, sold out of 12, added to 13 and reduced 14. The biggest buy was Apogee Therapeutics (APGE, shares +171%) and the biggest sale an exit from Immunocore Holdings PLC-ADR (IMCR).
- Most Recent 13F
- Q2 2026
- Location
- STAMFORD, CT
- CIK
- 0001920938
- Portfolio Value
- $1.8B (Q1 2024)
- SEC Filing
- 0001920938-24-000004 ↗ filed May 15, 2024
Holdings Value
Holdings 51 stocks · $1.8B
| APGE Apogee Therapeutics Inc. | 6.90% | 1,842,515 | $122.4M | Add +170.5% |
| NBIX Neurocrine Biosciences Inc. | 5.68% | 730,209 | $100.7M | Add +2.1% |
| ARGX Argenx SE - ADR | 4.88% | 219,824 | $86.5M | Add +43.5% |
| PCVX Vaxcyte Inc. | 4.67% | 1,212,703 | $82.8M | Reduce -6.0% |
| LEGN Legend Biotech Corp.-ADR | 3.93% | 1,243,795 | $69.8M | Add +121.1% |
| PEN Penumbra Inc. | 3.72% | 295,892 | $66.0M | Add +32.8% |
| MRVI Maravai Lifesciences Hldgs-A | 3.53% | 7,221,960 | $62.6M | Add +43.3% |
| VKTX Viking Therapeutics Inc. | 3.30% | 713,100 | $58.5M | New |
| XENE Xenon Pharmaceuticals Inc. | 3.17% | 1,308,011 | $56.3M | Reduce -20.6% |
| IRTC Irhythm Holdings Inc. | 3.16% | 483,257 | $56.1M | Reduce -14.9% |
| ALGN Align Technology Inc. | 3.13% | 169,252 | $55.5M | Add +15.7% |
| GH Guardant Health Inc. | 2.88% | 2,476,804 | $51.1M | Add +226.4% |
| CGON CG Oncology Inc. | 2.80% | 1,130,235 | $49.6M | New |
| KROS Keros Therapeutics Inc. | 2.75% | 737,379 | $48.8M | Reduce -34.1% |
| TMDX Transmedics Group Inc. | 2.56% | 614,531 | $45.4M | Add +422.1% |
| AVDL Avadel Pharmaceuticals plc | 2.54% | 2,668,549 | $45.1M | New |
| GKOS Glaukos Corp. | 2.40% | 450,676 | $42.5M | Add +85.7% |
| FNA Paragon 28 Inc. | 2.34% | 3,365,609 | $41.6M | Add +0.1% |
| ISRG Intuitive Surgical Inc. | 2.26% | 100,500 | $40.1M | New |
| DAWN Day One Biopharmaceuticals I | 2.02% | 2,173,704 | $35.9M | Reduce -48.4% |
| FDMT 4D Molecular Therapeutics Inc. | 1.89% | 1,052,485 | $33.5M | New |
| KIDS Orthopediatrics Corp. | 1.82% | 1,107,770 | $32.3M | No change |
| KRYS Krystal Biotech Inc. | 1.78% | 177,089 | $31.5M | Reduce -9.7% |
| RLAY Relay Therapeutics Inc. | 1.75% | 3,743,999 | $31.1M | New |
| IRWD Ironwood Pharmaceuticals Inc. | 1.71% | 3,489,843 | $30.4M | New |
| KNSA Kiniksa Pharmaceuticals Ltd. | 1.55% | 1,392,716 | $27.5M | New |
| TMO Thermo Fisher Scientific Inc. | 1.54% | 47,149 | $27.4M | Reduce -37.8% |
| RGEN Repligen Corp. | 1.48% | 142,836 | $26.3M | Add +39.1% |
| NVRO Nevro LLC filed as NEVRO CORP | 1.45% | 1,776,368 | $25.7M | No change |
| INSP Inspire Medical Systems Inc. | 1.23% | 101,492 | $21.8M | Reduce -45.0% |
| CGEM Cullinan Therapeutics Inc. | 1.19% | 1,240,865 | $21.1M | No change |
| TRML Tourmaline Bio Inc. | 1.17% | 906,820 | $20.8M | No change |
| LXEO Lexeo Therapeutics Inc. | 1.17% | 1,322,277 | $20.7M | New |
| SYRE Spyre Therapeutics Inc. | 1.10% | 515,000 | $19.5M | No change |
| BMRN Biomarin Pharmaceutical Inc. | 1.08% | 218,896 | $19.1M | New |
| GPCR Structure Therapeutics Inc. | 1.05% | 435,823 | $18.7M | Add +55.6% |
| BCRX Biocryst Pharmaceuticals Inc. | 0.97% | 3,379,577 | $17.2M | Reduce -40.9% |
| ITOS Iteos Therapeutics Inc. | 0.89% | 1,162,374 | $15.9M | New |
| MLYS Mineralys Therapeutics Inc. | 0.83% | 1,147,154 | $14.8M | Reduce -43.3% |
| ALEC Alector Inc. | 0.81% | 2,380,704 | $14.3M | Reduce -28.4% |
| ARQT Arcutis Biotherapeutics Inc. | 0.73% | 1,300,000 | $12.9M | New |
| ELEV Elevation Oncology Inc. | 0.69% | 2,377,647 | $12.2M | New |
| BBIO Bridgebio Pharma Inc. | 0.60% | 344,827 | $10.7M | New |
| IOVA Iovance Biotherapeutics Inc. | 0.55% | 660,022 | $9.8M | New |
| DCPH Deciphera Pharmaceuticals Inc. | 0.54% | 609,643 | $9.6M | Reduce -47.9% |
| OLMA Olema Pharmaceuticals Inc. | 0.45% | 704,344 | $8.0M | New |
| LUNG Pulmonx Corp. | 0.39% | 752,541 | $7.0M | Reduce -4.5% |
| DBV TECHNOLOGIES S A | 0.33% | 7,843,285 | $5.9M | No change |
| OM Outset Medical Inc. | 0.30% | 2,400,427 | $5.3M | No change |
| ADPT Adaptive Biotechnologies | 0.25% | 1,357,490 | $4.4M | No change |
| HROW Harrow Inc. | 0.09% | 125,967 | $1.7M | Reduce -91.6% |
Other holdings (19): bonds, preferreds, convertibles and warrants · $1.3B (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GUARDANT HEALTH INC (GH 0 11/15/27) | NOTE 11/1 · principal | 268,252,000 | $183.6M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 135,838,000 | $146.2M | Add +18.8% |
| EXACT SCIENCES CORP (EXAS 0.375 03/01/28) | NOTE 0.375% 3/0 · principal | 144,000,000 | $133.1M | Add +9.9% |
| NOVOCURE LTD (NVCR 0 11/01/25) | NOTE 11/0 · principal | 135,834,000 | $124.6M | No change |
| NUVASIVE INC (GMED 0.375 03/15/25) | NOTE 0.375% 3/1 · principal | 114,206,000 | $109.0M | Add +41.8% |
| NEOGENOMICS INC (NEO 0.25 01/15/28) | NOTE 0.250% 1/1 · principal | 103,580,000 | $82.6M | Add +57.9% |
| DEXCOM INC (DXCM 0.25 11/15/25) | NOTE 0.250%11/1 · principal | 65,000,000 | $71.6M | Add +44.4% |
| INSMED INC (INSM 1.75 01/15/25) | NOTE 1.750% 1/1 · principal | 64,887,000 | $69.4M | Add +23.9% |
| INSULET CORPORATION (PODD 0.375 09/01/26) | NOTE 0.375% 9/0 · principal | 66,000,000 | $68.9M | Add +4.8% |
| SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27) | NOTE 1.250% 9/1 · principal | 50,666,000 | $59.3M | No change |
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 67,294,000 | $55.1M | No change |
| IRONWOOD PHARMACEUTICALS (IRWD 1.5 06/15/26) | NOTE 1.500% 6/1 · principal | 52,740,000 | $53.7M | Add +240.3% |
| TRAVERE THERAPEUTICS INC (TVTX 2.5 09/15/25) | NOTE 2.500% 9/1 · principal | 56,031,000 | $49.6M | No change |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 65,976,000 | $35.8M | No change |
| ALPHATEC HOLDINGS INC (ATEC 0.75 08/01/26) | NOTE 0.750% 8/0 · principal | 32,434,000 | $33.9M | Add +21.3% |
| IRONWOOD PHARMACEUTICALS (IRWD 0.75 06/15/24) | NOTE 0.750% 6/1 · principal | 20,000,000 | $19.9M | Reduce -46.7% |
| HAEMONETICS CORP (HAE 0 03/01/26) | NOTE 3/0 · principal | 21,500,000 | $19.8M | New |
| CUTERA INC (CUTR 4 06/01/29) | NOTE 4.000% 6/0 · principal | 29,000,000 | $6.4M | No change |
| CUTERA INC (CUTR 2.25 06/01/28) | NOTE 2.250% 6/0 · principal | 25,240,000 | $5.7M | Reduce -20.9% |
Total filed on the 13F, all lines: $3.1B.
Portfolio Sells Q4 2023 → Q1 2024
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −3.16 |
| DAWN Day One Biopharmaceuticals I | Reduce -48.4% | 2.02% | −2.63 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -20.6% | 3.17% | −2.56 |
| LNTH Lantheus Holdings Inc. | Sold out | 0.00% | −2.32 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -40.9% | 0.97% | −1.62 |
| INSP Inspire Medical Systems Inc. | Reduce -45.0% | 1.23% | −1.61 |
| TMO Thermo Fisher Scientific Inc. | Reduce -37.8% | 1.54% | −1.49 |
| PCVX Vaxcyte Inc. | Reduce -6.0% | 4.67% | −1.45 |
| IRTC Irhythm Holdings Inc. | Reduce -14.9% | 3.16% | −1.44 |
| AMGN Amgen Inc. | Sold out | 0.00% | −1.27 |
| ALEC Alector Inc. | Reduce -28.4% | 0.81% | −1.20 |
| HROW Harrow Inc. | Reduce -91.6% | 0.09% | −1.17 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.14 |
| THRD Third Harmonic Bio Inc. | Sold out | 0.00% | −1.09 |
| DCPH Deciphera Pharmaceuticals Inc. | Reduce -47.9% | 0.54% | −0.89 |
| MRUS Merus NV | Sold out | 0.00% | −0.77 |
| DYN Dyne Therapeutics Inc. | Sold out | 0.00% | −0.76 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −0.75 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.73 |
| KROS Keros Therapeutics Inc. | Reduce -34.1% | 2.75% | −0.61 |
| VRDN Viridian Therapeutics Inc. | Sold out | 0.00% | −0.53 |
| MLYS Mineralys Therapeutics Inc. | Reduce -43.3% | 0.83% | −0.48 |
| LUNG Pulmonx Corp. | Reduce -4.5% | 0.39% | −0.37 |
| HLVX Hillevax Inc. | Sold out | 0.00% | −0.25 |
| KRYS Krystal Biotech Inc. | Reduce -9.7% | 1.78% | −0.06 |
| CMPX Compass Therapeutics Inc. | Sold out | 0.00% | −0.04 |
Portfolio Buys Q4 2023 → Q1 2024
| APGE Apogee Therapeutics Inc. | Add +170.5% | 6.90% | +5.46 |
| VKTX Viking Therapeutics Inc. | New | 3.30% | +3.30 |
| CGON CG Oncology Inc. | New | 2.80% | +2.80 |
| AVDL Avadel Pharmaceuticals plc | New | 2.54% | +2.54 |
| ISRG Intuitive Surgical Inc. | New | 2.26% | +2.26 |
| FDMT 4D Molecular Therapeutics Inc. | New | 1.89% | +1.89 |
| TMDX Transmedics Group Inc. | Add +422.1% | 2.56% | +1.86 |
| RLAY Relay Therapeutics Inc. | New | 1.75% | +1.75 |
| IRWD Ironwood Pharmaceuticals Inc. | New | 1.71% | +1.71 |
| KNSA Kiniksa Pharmaceuticals Ltd. | New | 1.55% | +1.55 |
| LEGN Legend Biotech Corp.-ADR | Add +121.1% | 3.93% | +1.37 |
| GH Guardant Health Inc. | Add +226.4% | 2.88% | +1.33 |
| LXEO Lexeo Therapeutics Inc. | New | 1.17% | +1.17 |
| BMRN Biomarin Pharmaceutical Inc. | New | 1.08% | +1.08 |
| MRVI Maravai Lifesciences Hldgs-A | Add +43.3% | 3.53% | +1.03 |
| GKOS Glaukos Corp. | Add +85.7% | 2.40% | +0.94 |
| ITOS Iteos Therapeutics Inc. | New | 0.89% | +0.89 |
| ARQT Arcutis Biotherapeutics Inc. | New | 0.73% | +0.73 |
| ELEV Elevation Oncology Inc. | New | 0.69% | +0.69 |
| BBIO Bridgebio Pharma Inc. | New | 0.60% | +0.60 |
| IOVA Iovance Biotherapeutics Inc. | New | 0.55% | +0.55 |
| ARGX Argenx SE - ADR | Add +43.5% | 4.88% | +0.47 |
| OLMA Olema Pharmaceuticals Inc. | New | 0.45% | +0.45 |
| GPCR Structure Therapeutics Inc. | Add +55.6% | 1.05% | +0.19 |
| ALGN Align Technology Inc. | Add +15.7% | 3.13% | +0.10 |
| RGEN Repligen Corp. | Add +39.1% | 1.48% | +0.09 |
| PEN Penumbra Inc. | Add +32.8% | 3.72% | −0.51 |
| FNA Paragon 28 Inc. | Add +0.1% | 2.34% | −0.82 |
| NBIX Neurocrine Biosciences Inc. | Add +2.1% | 5.68% | −1.45 |
Notes & Other Activity Q4 2023 → Q1 2024
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | Add +18.8% | 135,838,000 | $146.2M |
| EXACT SCIENCES CORP (EXAS 0.375 03/01/28) | NOTE 0.375% 3/0 · principal | Add +9.9% | 144,000,000 | $133.1M |
| ASCENDIS PHARMA A/S (ASND 2.25 04/01/28) | NOTE 2.250% 4/0 · principal | Sold out | 126,897,000 | $130.4Mbefore exit |
| NUVASIVE INC (GMED 0.375 03/15/25) | NOTE 0.375% 3/1 · principal | Add +41.8% | 114,206,000 | $109.0M |
| NEOGENOMICS INC (NEO 0.25 01/15/28) | NOTE 0.250% 1/1 · principal | Add +57.9% | 103,580,000 | $82.6M |
| DEXCOM INC (DXCM 0.25 11/15/25) | NOTE 0.250%11/1 · principal | Add +44.4% | 65,000,000 | $71.6M |
| INSMED INC (INSM 1.75 01/15/25) | NOTE 1.750% 1/1 · principal | Add +23.9% | 64,887,000 | $69.4M |
| INSULET CORPORATION (PODD 0.375 09/01/26) | NOTE 0.375% 9/0 · principal | Add +4.8% | 66,000,000 | $68.9M |
| TANDEM DIABETES CARE INC (TNDM 1.5 05/01/25) | NOTE 1.500% 5/0 · principal | Sold out | 71,051,000 | $67.2Mbefore exit |
| IRONWOOD PHARMACEUTICALS (IRWD 1.5 06/15/26) | NOTE 1.500% 6/1 · principal | Add +240.3% | 52,740,000 | $53.7M |
| ALPHATEC HOLDINGS INC (ATEC 0.75 08/01/26) | NOTE 0.750% 8/0 · principal | Add +21.3% | 32,434,000 | $33.9M |
| IRONWOOD PHARMACEUTICALS (IRWD 0.75 06/15/24) | NOTE 0.750% 6/1 · principal | Reduce -46.7% | 20,000,000 | $19.9M |
| HAEMONETICS CORP (HAE 0 03/01/26) | NOTE 3/0 · principal | New | 21,500,000 | $19.8M |
| INVITAE CORP (NVTA 2 09/01/24) | NOTE 2.000% 9/0 · principal | Sold out | 16,781,000 | $14.9Mbefore exit |
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | Sold out | 16,850,000 | $11.1Mbefore exit |
| NEOGENOMICS INC (NEO 1.25 05/01/25) | NOTE 1.250% 5/0 · principal | Sold out | 10,000,000 | $9.4Mbefore exit |
| CUTERA INC (CUTR 2.25 06/01/28) | NOTE 2.250% 6/0 · principal | Reduce -20.9% | 25,240,000 | $5.7M |
| IONIS PHARMACEUTICALS IN (IONS 0 04/01/26) | NOTE 4/0 · principal | Sold out | 5,240,000 | $5.5Mbefore exit |
| NANOSTRING TECHNOLOGIES (NSTG 2.625 03/01/25) | NOTE 2.625% 3/0 · principal | Sold out | 3,650,000 | $2.7Mbefore exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 83 | $2.6B | CAI, HNGE, GKOS, EWTX, SYRE |
| Q1 2026 | 82 | $2.6B | CAI, NBIX, GKOS, CNTA, XENE |
| Q4 2025 | 68 | $2.6B | CAI, EWTX, NBIX, GKOS, NUVL |
| Q3 2025 | 64 | $2.5B | CAI, XENE, CGON, NBIX, KRYS |
| Q2 2025 | 45 | $2.1B | CAI, NBIX, XENE, ARGX, KRYS |
| Q1 2025 | 52 | $1.9B | NBIX, LEGN, ARGX, XENE, ALGN |
| Q4 2024 | 59 | $2.2B | NBIX, XENE, LEGN, CGON, GH |
| Q3 2024 | 65 | $2.3B | CGON, XENE, NBIX, APGE, APLS |
| Q2 2024 | 58 | $2.0B | NBIX, CGON, XENE, APGE, GH |
| Q1 2024 | 51 | $1.8B | APGE, NBIX, ARGX, PCVX, LEGN |